Title: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

Authors
Josep M Llovet\textsuperscript{1,2,3}, Robert Montal\textsuperscript{1}, Augusto Villanueva\textsuperscript{2,4}.

Affiliations
\textsuperscript{1}Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
\textsuperscript{2}Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
\textsuperscript{3}Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
\textsuperscript{4}Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Corresponding author
Josep M Llovet, Translational Research in Hepatic Oncology, IDIBAPS-Hospital Clinic, Rosselló 153, 08039, Barcelona, Catalonia, Spain; Tel. 0034-932.279.155; Email address: jmllovet@clinic.cat

Keywords: trial design; liver cancer; systemic therapies; FDA approval.

Electronic word count: 6756.

Number of figures and tables: 4 figures, 2 tables, 1 supplementary figure.

Financial support statement: JML is supported by grants from European Commission Horizon 2020 Program (HEPCAR, proposal number 667273-2), US Department of Defense (CA150272P3), National Cancer Institute (P30 CA196521), Spanish National Health Institute (SAF 2016-76390), Cancer Research UK – Asociación Española Contra el Cáncer (Accelerator Award-HUNTER-A26813), Samuel Waxman Cancer Research Foundation, Generalitat de Catalunya (AGAUR, SGR-1358). AV is supported by U.S. Department of Defense (CA150272P3) and Tisch Cancer Institute (Cancer Center Grant P30 CA196521). RM is supported by a FSEOM – Boehringer Ingelheim grant.

Conflict of interest statement: JML and AV are inventors of a patent for the immune molecular subclass in HCC. Dr Llovet is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb and Ipsen, and consulting fees from Eli Lilly, Bayer HealthCare
Pharmaceuticals, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Glycostest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, Sprink Pharmaceuticals, Nucleix and Cat-Fite pharmaceuticals.

Summary

Hepatocellular carcinoma (HCC) is a relevant cause of cancer-related mortality worldwide. Around half of HCC patients will receive systemic therapies during their lifetime. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal anti-tumoral efficacy, toxicity, or trials with lack of enrichment strategies. This trend has changed during the period 2016-18, when several compounds such as lenvatinib (in first line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line) showed clinical benefit. These successes came at a cost of increasing the complexity of decision-making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with single active agents has surpassed the threshold of 1 year and the field is facing encouraging outcomes ~2 years with sequential strategies. Overall survival (OS) remains as the main endpoint in phase III investigations, but as in other solid tumors, there is a clear need to define surrogate endpoints that both reliably recapitulate survival benefits and can be assessed prior additional efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to progression (TTP) with OS (R=0.84 and R=0.83, respectively). Nonetheless, significant differences in PFS were only followed by differences in survival in 3 out of 7 phase III studies. In these later cases, the magnitude of benefit for PFS was HR ≤ 0.6, and thus this threshold is herein proposed as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
Introduction

The incidence of hepatocellular carcinoma (HCC) is increasing and will soon surpass one million annual cases worldwide[1]. Up to 80% of HCC patients have concomitant liver cirrhosis, mainly as result of hepatitis B and C virus infection, alcohol abuse or non-alcoholic steatohepatitis in the context of metabolic syndrome[2]. Coexistence of cancer and cirrhosis in HCC is an essential hallmark that has shaped clinical trial design in HCC, as encapsulated in the Barcelona Clinic Liver Cancer (BCLC) algorithm[3,4]. Only 40% of HCC patients are diagnosed at early stages, when potentially curative treatments (i.e. resection, liver transplantation and local ablation) are applicable[4]. As disease progresses, transarterial chemoembolization[5] (for intermediate HCC) and systemic targeted therapies[6] (for advanced HCC) have shown survival benefits. Since sorafenib positive impact in survival[7], at least 10 trials have shown negative results in front-line. In the last 2 years, however, numerous systemic agents have demonstrated clinical benefit in the context of phase III trials. The fact that six drugs are currently effective and/or approved by the Food and Drug Administration (FDA) for the management of advanced HCC poses a challenge for assessing novel strategies in this arena in terms of trial design. Overall survival (OS) is an unquestionable, unbiased primary endpoint in oncology and in all randomized studies testing systemic therapies in first and second line in advanced HCC[7-27]. However, other solid tumors have identified surrogate endpoints of survival that led to accelerated and regular approval, notably objective response rate (ORR) and progression free survival (PFS)[28,29]. These endpoints are aimed to recapitulate survival benefits with the advantage of being assessed prior additional efficacious drugs are administered. By thoroughly analyzing the past experience since sorafenib approval, we have assessed the correlation between surrogate endpoint such PFS, time to progression (TTP) and ORR with clinically meaningful improvements in OS in 21 reported phase III studies[7-27]. Based on this analysis and a conservative approach to define surrogates of OS in HCC, we propose PFS with a threshold of HR≤ 0.6 as reliable surrogate with solid positive predictive value, whereas the threshold of HR=0.6-0.7 -despite leading to positive statistical results- is defined as clinically uncertain in terms of capturing true advantages in OS. In addition, we revisit the correlation between ORR by mRECIST and OS and define again that ORR is an independent predictor of OS at early, intermediate and advanced stages, meaning that responders survive significantly longer. Nonetheless, ORR is still a suboptimal tool as surrogate due to the low sensitivity in capturing those patients that benefit from a given drug. Ultimately, we envision providing a historical perspective of HCC trial design, which are the lessons to be learned, and how to maximize clinical trials success in the near future.

Overview of phase III and practice-changing phase II trials reported during the last 10 years

Current estimates suggest that around 50% of HCC patients will receive systemic therapies at one time point or another during their lifespan [2,4,30]. Several trials have tried to show survival
benefits of systemic agents in advanced disease, a traditionally challenging setting due to the limit
efficacy and high toxicity of conventional systemic chemotherapy[16–18,31]. Randomized studies
also failed to prove any clinical efficacy for anti-estrogen therapies[32]. In 2008, the landmark
SHARP trial assessing the multi-tyrosine kinase inhibitor sorafenib (VEGFRs, PDGFRs, RAF and
KIT) was the first to significantly expand survival (hazard ratio (HR) of 0.69) with manageable
adverse events[7]. Similar efficacy was demonstrated in the phase III trial testing sorafenib in Asian
patients[8]. These successful results helped established contemporary concepts in trial design that
have been implemented in phase III trials over the succeeding years (Table 1 and Figure 1)[33].
The main concepts implemented in these trials are: a) selection of patients with well-preserved liver
function (i.e., Child-Pugh A class) to minimize the competing risk of liver failure and death as a
result of the natural history of cirrhosis; b) restriction of the investigational niches to those stages
with unmet medical needs such as advanced stage (BCLC C), or intermediate stage (BCLC B)
progressing after TACE in case of systemic treatments or adjuvant setting after resection/local
ablation; c) use of OS as the cornerstone primary endpoint to assess efficacy in advanced stages,
and d) use of critical prognostic factors as tools for stratification prior randomization based upon
ECOG 0 vs 1, macrovascular invasion, extrahepatic spread, and alpha-fetoprotein (AFP) levels
(>400 ng/ml). Etiology is not considered a prognostic factor, but needs to be incorporated when
testing sorafenib, since it has been demonstrated to be a predictor of response for this drug, at the
same level than absence of extrahepatic spread and low neutrophil-to-lymphocyte ratio[34].

In this context, new treatment modalities emerged to challenge sorafenib in first-line or
placebo in second-line. These include brivanib (VEGFRs and FGFRs)[10,19], sunitinib (VEGFRs,
PDGFRs and KIT)[9], linifanib (VEGFRs and PDGFRs)[11], erlotinib (EGFR) in combination to
sorafenib[12], everolimus (mTOR)[20], tivantinib (MET)[23], doxorubicin loaded nanoparticles[27]
and ADI-PEG 20 (arginine deiminase enzyme)[26] (Table 1). All of them had disappointing results
and it was not until 2016 that the RESORCE study led to the first positive phase III trial in advanced
HCC for nearly a decade. Regorafenib (VEGFRs, PDGFRs, KIT and Tie2) improved OS compared
to placebo from 7.8 to 10.6 months in patients who progressed and were tolerant to sorafenib[22].
Notably, OS from starting sorafenib follow by regorafenib was 26 months compared to 19 months
for sorafenib followed by placebo for patients with advanced HCC [35]. Besides regorafenib, other
phase III clinical trials have recently improved OS in second-line when compared to placebo: The
CELESTIAL study, showing median OS of 10.2 months with cabozantinib (VEGFRs, MET and
AXL) vs 8 months with placebo[24]; and the REACH-2 study, where ramucirumab (VEGFR2
monoclonal antibody) provided a median OS of 8.5 months in patients with AFP equal or higher
than 400 ng/ml vs 7.3 months with placebo[21,25]. AFP is well-known for its independent prognostic
capacity in HCC[36]. As such, REACH-2 becomes the first positive phase III trial in a biomarker-
driven population of HCC patients. In parallel, lenvatinib (VEGFRs, FGFRs, RET, KIT and
PDGFRA) has become an option in frontline after the positive result of the non-inferiority REFLECT
study[13]. In contrast, three phase III trials testing internal radiation with Y-90 for advanced HCC, either as single treatment [SARAH[14] and SIReN[15]] or in combination Y-90 plus sorafenib[37] did not meet the primary endpoint of improved OS compared to sorafenib. As a result, Y-90 is discouraged for the management of advanced HCC in the recent EASL guidelines[4].

Finally, the FDA has granted accelerated approval to the immune checkpoint inhibitor nivolumab (monoclonal antibody against PD1) in second-line after a large phase II single-arm trial showing promising ORR of 14% by RECIST (responses lasting more than 12 months in 55% of cases)[38,39]. Pembrolizumab has recently shown an ORR of 17% and median OS of 12.9 months in the second-line setting[40]. The revolution of immune therapies that has changed the paradigm of treatment in oncology is now finding its way in HCC, with ongoing phase III in both first- (NCT02571509, NCT03298451, NCT03434379, NCT03713593) and second-line (NCT02702401) targeting key mediators of the anti-cancer immune response (e.g., PD1, PDL1, CTLA4, LAG3). Overall, these successful results have amplified the number of effective drugs available to clinicians for the management of advanced HCC (Figure 2). New studies will be crucial to ascertain the most efficient way to utilize these drugs and maximize clinical benefit.

**Reasons for positive/negative results in phase III investigations**

**Negative phase III clinical trials**

Until 2016, sorafenib was the only systemic agent able to significantly increase survival in patients with advanced HCC[7]. This was despite numerous attempts to improve, or parallel (i.e., non-inferiority trials), its efficacy and develop new second-line therapies in the context of phase III trials (Table 1). Until then none of the 8 randomized clinical trials (RCTs) testing systemic treatments (vs sorafenib in front line[9–12,17] or placebo in second-line[19–21]) was able to achieve positive results. Nowadays, 6 of 21 (29%) trials have been able to meet the primary endpoint and potentially change the standard of care. This success rate is lower than in other tumor types, with reported success rate of 37%[41], and resonates with the difficulties of developing effective drugs in HCC. Negative HCC trials enrolled a total of 8,604 patients and consumed a significant amount of resources. Failed drugs include linifanib[11], erlotinib[12], brivanib[10,19], sunitinib[9], doxorubicin[17,27], everolimus[20], tivantinib[23], ADI-PEG 20[26] and radioembolization with Y-90[14,15] (Table 1). These drugs have different molecular targets, mechanisms of action, and include various treatment modalities (pharmacological vs radiation-based). Thus, it is likely that multiple reasons contributed to their failure, but we will dissect three key factors, reviewed in [42]: a) limited anti-tumoral efficacy (or biological activity), b) significant toxicity, and c) lack of effective enrichment strategies for patient enrollment.

**Limited anti-tumoral efficacy (or biological activity)**
The first factor relates to limited anti-tumoral activity of the drug as per its main molecular targets. This implies that either they have a marginal role in HCC progression, or their selective inhibition is insufficient to induce a significant clinical benefit. For instance, evidence from murine models demonstrated how aberrant activation of MTOR signaling promotes liver cancer[43], and how its selective abrogation has anti-tumoral effects in xenografts[44]. In human HCC, MTOR pathway is deregulated in up to 45% of samples[44,45], and yet, the phase III trial testing everolimus was unable to improve survival compared to placebo in second line with a HR for OS of 1.05[20]. Data in phase II already suggested a modest median survival of 8.4 months[46] associated to marginal response rates. Also, the companion biomarker study for the phase III trial failed to find any robust predictive biomarker of response to everolimus[47]. Altogether, these data suggest that MTOR inhibition has no anti-tumoral activity in advanced HCC. Other drugs potentially falling under this category include the EGFR inhibitor erlotinib[12], and the EGFR2/VEGFR inhibitor brivanib[10,19]. Limited efficacy can also be claimed for Y-90 resin microsphere treatment as a superior alternative to sorafenib. The phase III trials reported[14,15], were negative with a HR for OS of 1.1. It is important to note that failure to demonstrate superiority does not mean similar efficacy, which requires an ad hoc trial design for non-inferiority or equivalence, a concept that will be further discussed in this review[48].

Drug toxicity

The second reason is significant drug toxicity, which is relevant in cirrhotic patients since liver dysfunction decreases the threshold for severe adverse effects. The best example is sunitinib[49], that despite having a molecular target profile similar to sorafenib, it was unable to improve survival when compared in frontline[9]. The trial was prematurely terminated due to futility and safety concerns affecting sunitinib. Median OS for sunitinib was 7.9 months, compared to the 10.2 with sorafenib (HR of 1.3). Treatment-related deaths occurred in 3.2% and 0.4% of patients receiving sunitinib and sorafenib, respectively. When this trial was conducted, sunitinib was already FDA approved for advanced kidney cancer and gastrointestinal stromal tumors, where toxicity was not a major clinical issue. However, in patients with underlying liver disease the toxicity of sunitinib was severe enough to obscure any beneficial anti-tumoral efficacy. Sunitinib has a higher inhibitory potency than sorafenib, particularly regarding its anti-angiogenic activity via VEGFR and PDGFR Inhibition[50]. Angiogenesis is critical during liver fibrogenesis[51], so the strong and sustained anti-angiogenic effect achieved with sunitinib seems detrimental, favoring liver failure. Previous phase II trials testing sunitinib in HCC offer additional insights into the hepatic toxicity of this drug[52–54], including up to 4/37 (11%) treatment-related deaths[54]. An adequate identification of toxicity signals at this stage could help mitigate this problem. Another example is the VEGFR/PDGFR inhibitor linifanib, tested in frontline versus sorafenib[11]. This trial was early terminated based on futility (median OS for linifanib and sorafenib were 9.1 and 9.8 months), but grade 3-4 adverse events were significantly more frequent in linifanib than in sorafenib, including hypertension (21% vs
11%) and hepatic encephalopathy (7% vs 3%). Besides the negative effect of toxicity in clinical outcomes, there is a subtler effect of non-lethal toxicity as it associates with dose reductions, which could also decrease antitumor potency.

**Lack of trial enrichment strategies**

A third reason for clinical trial failure is lack of effective enrichment strategies for patient enrollment based on predicted biomarkers of response. Trial enrichment in oncology is closely linked to the concept of oncogene addiction. This term describes those molecular alterations, generally DNA mutations or chromosomal aberrations, required for cancer cell proliferation and survival[55]. There are numerous examples in oncology of survival benefits after a clinical trial testing a drug only in those patients with mutations in its target[56] (e.g., ALK rearrangements in lung cancer and response to crizotinib[57]). Only 2/21 (10%) phase III trials in advanced HCC incorporated patient enrichment, likely due to: a) limited access to tumor tissue in patients already diagnosed by noninvasive criteria; and b) few druggable targets among the most common genetic alterations in HCC[58,59]. In fact, the most common mutations in HCC (**TERT** promoter, **CTNNB1**, **TP53**, **AXIN1**, **ARID1A** and **ARID1B**) are untargetable[2,60]. One of them evaluated tivantinib versus placebo in second line in patients with high expression of MET assessed with immunohistochemistry[23]. This trial was based on a post-hoc analysis of 37 patients from a previous phase 2 trial[61] and failed to meet its primary endpoint with a HR for OS of 0.97. Arguably, the signal in the phase 2 trial was weak, but most important, recent data questions the specificity of tivantinib as a MET inhibitor[62]. It was also thought that MET was a prognostic factor, but the median survival of 9.1 months for the placebo arm in MET-high patients in second-line challenges this concept[23]. The second trial tested the **VEGFR2** monoclonal antibody ramucirumab versus placebo in second line (i.e. **REACH-2**) in patients with **AFP** higher than 400 ng/mL, and showed a significant improvement in OS versus placebo (HR of 0.71[25]). A difference with the tivantinib case is that the rationale for **REACH-2** came from a post hoc analysis of the negative phase III trial in all-comers (i.e., **REACH[21]**) which enrolled 565 patients. This showed a robust p of interaction favoring ramucirumab in patients with high **AFP** of 0.02. **AFP** is a well-known poor prognostic marker[36,47], highly expressed in tumors with a supposed progenitor cell origin[63], but it does not provide a neat link between any specific driver oncogenic event (i.e., structural DNA alteration or signaling pathway) and ramucirumab’s main molecular target. Experimental evidence identifies **VEGFR2** as a marker of hepatic progenitors[64], which could hypothetically explain the efficacy of ramucirumab in tumors with high **AFP**.

**Positive phase III clinical trials**

Successful drugs in frontline include sorafenib and lenvatinib, whereas regorafenib, cabozantinib, and ramucirumab in patients with high **AFP** demonstrated efficacy in second line (Table 1 and Figure 2). The PD1 inhibitor nivolumab has shown promising results in phase II with an
ORR of 14% by RECIST (18% by mRECIST) and a median OS of 15.6 months [38,65], which granted its accelerated approval by the FDA. Another immune-based therapy - pembrolizumab-reported similar ORR (17%) but lower median OS (12.9 months[40]). Data from phase III trials in first-line (nivolumab vs sorafenib) and in second-line (pembrolizumab vs placebo) will be critical to fully recommend these immune-based therapies in clinical practice guidelines[4]. Since the strength of evidence so far comes from phase II data, current EASL guidelines just posed a weak recommendation for nivolumab[4].

The reasons for trial failure provide the best clues for the qualities of a drug to be successful in HCC, which essentially are: a) adequate clinical trial design with an emphasis on selection criteria and robust endpoints; b) a fine balance between drug efficacy and toxicity; and c) a proper interpretation of efficacy and toxicity signals in phase II trials. Sorafenib epitomizes these qualities, and to certain extent, the design principles implemented in the pivotal SHARP trial[7] were adopted as best-practices for design in subsequent studies[33]. The target population must include patients with well-preserved liver function (i.e., Child-Pugh A with compensated liver disease) to avoid competing risks from deaths due to progression of the liver disease, and to minimize drug toxicity. Also, patients need to be fit enough to tolerate the drug and with a life expectancy of at least 3 months, which can be reasonably guaranteed by enrolling patients with ECOG performance status test (PST) of 0-1. It is paramount to enroll patients at the same clinical stage as per the BCLC classification[4,66]. The SHARP trial was instrumental to eradicate the misleading concept of ‘unresectable’ HCC when conducting HCC trials. This concept included a heterogeneous population of patients at intermediate (BCLC-B) and advanced (BCLC-B) stages[67], which imposed significant bias when interpreting trial results. In addition to the same clinical stage, patients need to be adequately stratified for known HCC prognostic factors and geographic region.

Regarding patient’s selection, the success of the REACH-2 trial underscores the importance of properly interpreting post hoc analysis. The pooled analysis of REACH and REACH-2 assessing ramucirumab in those patients with AFP > 400 ng/mL further confirms a significant and clinically meaningful benefit of ramucirumab vs placebo in second-line (median survival 8.1 vs 5 months; HR=0.694)[25]. The rationale to enrich trials based on predicted oncogene addiction is two-fold: first, to maximize anti-tumoral response by perturbing the cancer drivers active in a given patient, and second, to spare unnecessary toxicity in those patients without the oncogene addiction. HCC has few druggable targets among the most frequent driver mutations, but a recent proof-of-concept trial reinforces the validity of this approach to explore treatment response[68]. A screening of 1,318 HCC patients allowed enrolling 54 cases with RAS mutations (4.4%) detected using circulating tumor DNA (ctDNA) in a phase II trial testing the combination of sorafenib with the MEK inhibitor refametinib[68]. Mutation analysis of ctDNA is feasible in HCC[69] and facilitates screening of large populations. Other potential druggable oncogenic alterations in HCC include high-level DNA amplifications of FGF19[70,71] or VEGFA[70,72]. Phase II clinical trials are currently exploring
selective inhibition of these candidate oncogene addition loops[73]. There is also increasing interest in developing biomarkers to identify the 20% of patients who respond to immune-based therapies, who show outstanding OS. The use of PD-L1 staining seems irrelevant in HCC[38], and other potential biomarkers such as tumor mutational burden (TMB)[74] or the HCC immune class[75] are under investigation. To facilitate the implementation of biomarker-based clinical trials in HCC, it is essential to enforce mandatory tissue collection in all clinical trials testing new compounds[4]. In this regard, the impact of intratumor heterogeneity in single-biopsy predictions is still debated despite recent studies have shown that driver gene mutations are common between different regions of the tumor[76,77].

Traditionally, new therapies were compared with standard of care or placebo to demonstrate greater efficacy of the new drug. Despite this is the recommended trial design practice in HCC[4,33], some studies after SHARP used non-inferiority designs to challenge sorafenib in first-line. The hypothesis in non-inferiority trials is that the new compound is not substantially worse than the current standard, as opposed to equivalence trials, which are designed to demonstrate that the experimental treatment is neither worse not better than the standard therapy[78]. Non-inferiority trials are required to claim similar efficacy as opposed to assuming it from a negative superiority trial, as previously explained for the Y-90 trials. The non-inferiority trial scenario in HCC is extensively described elsewhere[42], and caveats include the need for larger sample sizes and a very small window of opportunity, as defined by the tight non-inferiority margins. For instance, the BRISK-FL trial was designed to demonstrate non-inferiority of brivanib compared to sorafenib in first line[10]. The trial assumptions set the upper limit of the 95% confidence interval of HR for OS to 1.08. To call non-inferiority, the HR could cross 1, but the upper boundary needed to fall between 1 and 1.08. This threshold is very stringent and can be interpreted as the requirement to demonstrate a robust non-significant trend towards superiority for the new drug. The value proposed by FDA has been calculated based upon capturing at least >60% of the survival benefit obtained with sorafenib[13]. The BRISK-FL trial did not meet this endpoint since the HR confidence interval limits for OS were 0.94 and 1.23. The concept of non-inferiority trials introduces other considerations in treatment recommendations such as toxicity or cost, which will surely contribute to frame the landscape of systemic therapies in HCC.

**Hard and surrogate endpoints: Implications in clinical trial design**

The overarching goal of oncological treatments is to allow patients to live longer and better lives than they would do without treatment[79]. Thus, clinical research needs to unequivocally demonstrate statistically and clinically meaningful improvements of the experimental arm over the standard of care. Three types of endpoints have been defined: 1. Hard endpoints, such as overall survival and cancer-specific survival; 2. Surrogate endpoints such as PFS, TTP and ORR, and 3. Patient reported endpoints, such as quality of life (QOL).
Overall survival

This hard endpoint quantifies the time between random trial allocation and death, whatever the cause. Since is not subject to investigator bias, OS has been traditionally recommended by international HCC guidelines as the primary endpoint for randomized phase III trials testing new therapies[80]. In fact, all regular FDA drug approvals in advanced HCC were based upon improvements in OS [7,22]. Cancer-specific survival, where only deaths due to cancer are considered and noncancer-related deaths are censored, is more difficult to assess in conventional trial settings. Deaths due to competing risks, such as liver failure, require a subjective interpretation by the investigator, and thus are more prone to bias[33].

What is the magnitude of benefit to define it as clinically meaningful? This is a controversial topic, highly dependent on the expected outcome for the target population, with confronted opinions between patients, providers, regulatory agencies and health insurers [81,82]. In HCC, there is no consensus on what absolute survival benefit (or the magnitude of benefit in OS as per HR) to be defined as clinically relevant. Reported thresholds of OS with HR<0.8 are also sound for capturing the benefit of patients in advanced HCC trials[83].

Survival has some limitations as a sole endpoint in cancer research. First, it might require a long follow-up time to capture enough events due to significant improvement in median OS in the experimental arm[35]. This negatively impacts feasibility and delays access to patients to highly effective drugs. Second, it can be affected by sequential therapies received after tumor progression (post-progression survival), such as for instance regorafenib after a first-line therapy. This might involve one third of patients in recent phase III trials[13]. In this context, validation of surrogate endpoints of OS is paramount to facilitate trial execution and favor a quick deployment of effective drugs in routine clinical conditions.

Surrogate endpoints: PFS, TTP and ORR

Ideally, significant improvement in OS is preferred, but many drugs have been approved based on their ability to improve other less robust endpoints, termed surrogates (i.e., TTP, PFS and ORR). These are outcomes not inherently meaningful from the clinical standpoint, but thought to accurately predict hard outcomes such as OS[84]. The development of surrogate endpoints became a necessity in clinical trials in cardiology, where the long time to accumulate enough events for a hard endpoint made most studies unfeasible. Use of surrogate endpoints is becoming a need in oncology where effective post-progression therapies are available.

Accelerated approval based upon surrogate endpoints is becoming the most relevant path for cancer drug regulatory approval in the US. Between 2009 and 2014; the FDA approved 83 drugs in oncology, 66% of them on the basis of surrogate endpoints[85]. The FDA’s accelerated approval program was introduced in 1992 as a social compromise during the worse years of the HIV
epidemic to expedite access to agents for life-threatening conditions based on surrogate endpoints. The program included a "safety net" that required the manufacturer to conduct post-marketing studies and confirm the efficacy of the drug using hard endpoints[86]. A recent analysis of approved drugs during the period 1992-2017 led to the following conclusions[28]: a) Accelerated approval was granted for 93 indications, ORR being the most common surrogate endpoint used (87% of cases), b) Among drugs approved through this path, 55% were ultimately confirmed for regular approval, 5% of indications were withdrawn (e.g., bevacizumab in metastatic breast cancer[87]), whereas in others the process has not been concluded.

Despite the increasing importance of surrogate endpoints in oncology, they have two main limitations. First, since they usually rely on the radiological definition of tumor progression or response, they are vulnerable to interpretation bias. This can be minimized by using central radiology reviews and a designated adjudicator of response. Second, and more important, in order to be reliable, they require validation as credible predictors of OS[84]. Validation of surrogate endpoints can be conducted at the individual- or trial-levels[88]. While validation of individual-level surrogacy requires individual patient data from at least one clinical trial, trial-level surrogacy uses assembled data from multiple trials. The Institute for Quality and Efficiency in Health Care has proposed a set of criteria to quantify the association between a surrogate and hard endpoint, which includes low (R<0.7), moderate (R>0.7 to R<0.85) and high correlation (R>0.85)[89]. R refers to the weighted Pearson coefficient between HR of OS and HR of the surrogate endpoint. Alternative methods to study this correlation have been reported[90]. A systematic review and meta-analysis of trial-level surrogate endpoints (PFS, TTP and ORR) for OS in oncology including 36 articles and 352 clinical trials found low, moderate and high correlation with OS in 52%, 25% and 23% of surrogate endpoints, respectively[84].

In order to explore the concept of surrogate endpoints recapitulating OS in advanced HCC we have identified 21 RCTs assessing systemic therapies with or without loco-regional therapies in advanced HCC (12 in first-line and 9 in second-line) (Table 1) published between 2008 and 2018 through a MEDLINE search via PubMed using the keywords "advanced hepatocellular carcinoma". Results were limited to "clinical trial, phase III". Trials recently presented at international meetings (2016-2018) were also included despite the full manuscript is not yet available. For each trial, data on sample size, radiological response, TTP and OS were collected. TTP and OS were determined in terms of hazard ratio (HR) using published data (values less than 1 denotes a favourable result in the experimental group). In addition, ORR was established with odds ratio calculated from the published radiological response (values greater than 1 denotes a favourable result in the experimental group). For the purpose of the trial-level analysis, we first assessed the overall correlation between PFS and OS (R=0.84; R²=0.71) (Figure 3A), and then the correlation of TTP and OS (R=0.83; R²=0.69) (Figure 3B). Afterwards, we established a conservative threshold of positive predictive value for PFS since this is the most documented surrogate time-to-event
endpoint in oncology, and the one showing a higher correlation with OS[84]. Finally, we explored the correlation between ORR assessed as per mRECIST and survival in early, intermediate and advanced HCC.

**Progression-free survival**

PFS is a composite endpoint of two variables: death and evidence of radiological progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. International guidelines initially discouraged this endpoint in HCC due to the competing risk of dying due to progressed liver dysfunction despite a relevant anti-tumoral benefit[33]. However, this limitation has been mitigated since most trials in HCC have adopted restrictive inclusion criteria in terms of liver function (i.e., Child-Pugh A without decompensation). In this scenario, the likelihood of death as a result of liver decompensation (i.e., gastrointestinal bleeding, encephalopathy or ascites and spontaneous portonitis) is 5% at one year[93]. When we evaluate the association between PFS and OS in HCC phase III trials, we observe a moderate Pearson correlation (R) of 0.84 (Figure 3A). This figure falls in the upper boundary of a moderate correlation (R between 0.7 and 0.85). When specifically analyzing the positive predictive value of theoretical thresholds of PFS correlating with OS, only 3/7 PFS reported a HR ≤0.6 that was significantly associated with a positive survival clinical benefit (in all cases with a HR for OS < 0.8). Conversely, those four studies reporting a positive PFS with a HR between 0.6-0.8 were associated with no significant survival benefits (HR for OS between 0.87 and 1.05) (Figure 3A). In our study, according to the linear regression equation obtained [log HR_{OS} = 0.072 + 0.487 x log HR_{PFS}], a threshold of PFS HR=0.6 (representing a 40% risk reduction) will decrease ~17% the risk of OS (OS HR=0.83) (see Figure 3A). In summary, a moderate correlation has been established between PFS and OS in 21 RCTs in advanced HCC. A value of HR ≤0.6 is proposed as surrogate threshold effect [94], and is likely to predict a clinically meaningful improvement in OS. Is worth to mention though that this rule is supported mainly by positive trials in the second-line setting comparing active drugs vs placebo. We assume that such association is retained in front-line comparing two active drugs, but recommendation in that setting should be tempered due to the lack of confirmatory data.

**Time to progression**

This endpoint quantifies the time between trial allocation and radiological progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. Deaths are censored as non-radiological progressions at the time of death or at an earlier visit, with a cause-specific hazard, representing informative censoring. Symmetric repeated radiological measurements every 6-8 weeks are required to avoid missing moderate differences between treatment groups[33]. This recommendation was not followed in the SIRvenIB[15], SARAH[14] and ADI-PEG 20[26] trials.

To delineate the adequacy of TTP as a surrogate of OS in HCC we conducted also a trial-level meta-analysis to evaluate the correlation between TTP and OS in 21 RCTs (Figure 3B). The
Pearson correlation (R) was 0.83, which indicates a moderate association according to the IQWIG guidelines[84]. In 10 phase III trials there was a significant difference in TTP in favor of the investigational arm. However, these positive results in TTP were not followed by superiority in OS in 5 (50%) trials. Brivanib[19] and ramucirumab[21] in second-line showed efficacy as per TTP (HR=0.56 and 0.59, respectively), while not significantly improving the hard endpoint of OS (HR=0.89 and 0.87, respectively). Lenvatinib[13] in first-line versus sorafenib also showed significant differences in TTP favoring lenvatinib (HR 0.83), without showing superiority for OS (HR=0.92). This trial was positive since it was designed for non-inferiority (upper 95% CI lower than 1.08). Finally, linifanib[11] and hepatic infusion arterial chemotherapy (HAIC)[18] in first-line failed to show any benefit in terms of OS (HR=1.05 and 1.01, respectively) even though there was a clear benefit when measuring TTP (HR=0.76 and 0.65, respectively). These results do not support the initial recommendation after the SHARP trial of using TTP as the optimal surrogate endpoint[33] in phase 2 trials, and reinforce the need for accurate evaluation of surrogacy in clinical trials. Based on the linear regression model obtained [log HR<sub>OS</sub> = 0.083 + 0.491 x log HR<sub>TTP</sub>], we can extrapolate that a therapy producing a 40% risk reduction in TTP will yield an estimated ~16% risk reduction in OS (HR=0.84) (see Figure 3B). Moreover, in order to directly compare the performance of PFS and TTP, we analyzed the correlation between both surrogate endpoints, obtaining a Pearson correlation (R) of 0.99 (Figure 4). Thus, in the modern era of HCC trial design, with minimal cirrhosis-related deaths (due to the inclusion of Child-Pugh A), there is a strong correlation between both endpoints. In fact, when we inferred the non-reported PFS HR of SHARP and AP trials according to the linear equation obtained comparing both surrogate endpoints [log HR<sub>PFS</sub> = 0.014 + 0.927 x log HR<sub>TTP</sub>], the HRs values are close to 0.60, just at the previously proposed minimum threshold.

There are two other considerations regarding this endpoint. First, not all types of tumor progression may have the same clinical meaning. Recent data also suggest that TTP may capture heterogeneous features, with essentially two types of progression at advanced stages[95,96]. In particular, survival after progression is significantly worse for patients who develop a new extrahepatic lesion and/or vascular invasion (median OS = 7.1 months) compared to those who progress due to the growth of existing intrahepatic extrahepatic lesions or the development of a new intrahepatic lesion (median OS = 14.9 months). Second, factors including evaluation bias, trial attrition or informative censoring may weaken the association between the TTP and OS [29]. Finally, prolonged exposure to a given therapy might lead to a phenotypic change in tumors, thus, offsetting any initial advantage from the treatment captured by the surrogate endpoint[97].

**Objective response rate**

Tumor response in oncology trials is typically measured using the Response Evaluation Criteria in Solid Tumors (RECIST)[91]. These criteria standardize methods for converting radiological observations into a quantitative and statistically tractable framework to define tumor
response (i.e., a 30% decrease in the diameter of target lesion). ORR is the percentage of patients who achieve an objective tumor response. Disease control rate (DCR) is the combination of ORR and stable disease, but it has two disadvantages that limit its adoption for regulatory approval: a) the definition of duration of stable disease varies between studies; and b) stable disease can reflect inherent characteristics of the tumor rather than treatment efficacy.

The RECIST criteria were originally developed to evaluate cytotoxic agents. The generalization of targeted therapies has challenged this simplistic approach that relies on tumor shrinkage to indicate clinical efficacy. Sorafenib was associated with only 2-3% of ORR, despite providing clear survival benefits[7,8]. Given the poor correlation between tumor response assessed with conventional tools and OS, a group of experts convened by the American Association for the Study of Liver Diseases (AASLD) proposed specific amendments to standard RECIST[33]. Further description of response and progression resulted in the criteria named modified RECIST (mRECIST), which ultimately incorporates the concept of viable tumor defined as the portions of tumor showing arterial enhancement[92]. The mRECIST criteria in HCC have improved the sensitivity to quantify tumor response with targeted therapies: ORR of 9-17% with sorafenib[10,13,18], 10-12% with brivanib[10,19], 11% with regorafenib[22] and 24% with lenvatinib[13]. Retrospective studies have consistently demonstrated that patients who achieved an objective response on sorafenib had a longer survival than non-responders[98–100]. Recently, data from double-blind randomized trials assessing brivanib and nintedanib further validated this association [101,102]. Thus, the association between tumor response and improved OS in HCC patients at advanced stages complement what was already knew in patients at early and intermediate stages treated with loco-regional therapies[103–109](Table 2).

When we evaluate the trial-level correlation between ORR and OS (Supplementary Figure 1), the R weighted Pearson coefficient obtained is 0.54. This is significantly lower than the correlation obtained with PFS/TTP and OS as depicted in Figure 3. There are two reasons for this: one is inherent to the use of odds ratio instead of hazard ratio to compare differences in ORR. The accuracy of odds ratio decreases for low values of ORRs. The second reason is that only a small proportion of patients within these trials achieved ORR (~10-20%), which is, in fact, the event that correlates with better survival[101]. A direct comparison between RECIST and mRECIST for OS surrogacy through an independent meta-analysis of trials using either criteria would be ideal to define the role of ORR to predict OS in advanced HCC. This will also help determine the best tool to evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response data using mRECIST, we did not sub-analyze this endpoint according to the tool used to evaluate response.

Some other questions remain unanswered. As observed in other solid tumors treated with efficacious targeted therapies[110–112], the reported rates of responders are still suboptimal to estimate the maximum number of patients who would benefit from the treatment. In addition, the
duration of response might be more clinically relevant than the extent of tumor reduction. Finally, the strategy to evaluate response might require a thoughtful revision when assessing immunotherapies. As shown in melanoma patients treated with checkpoint inhibitors, standard RECIST may not provide a reliable assessment of antitumor efficacy[113]. In fact, response to immunotherapy may take longer compared to other agents and can even falsely mirror criteria for progression (i.e., pseudo-progression)[114]. Immune-related response criteria have been developed[115,116], including the concept of "confirmation of progression" by a second scan obtained at least 4 weeks after progressive disease has been registered.

Despite all the challenges that evaluation of tumor response face in oncology, and particularly in HCC, the importance of ORR as a surrogate endpoint is recognized by regulatory agencies and frequently used for accelerated drug approval. This was the case of nivolumab, approved in second-line based on an ORR of 18% by mRECIST and 14% by RECIST [38,39]. Remarkably, objective response to nivolumab has been associated with prolonged OS[65]. Overall, the fact that a high ORR in phase II trials was considered a robust criterion for drug approval[117], and further success in phase III trials[118], indicates that ORR should be considered as a primary endpoint for single-arm phase II studies. Related to this, early clinical trials are showing promising results with combinations of checkpoint inhibitors and targeted therapies, as measured by ORR. Lenvatinib plus pembrolizumab[119] and atezolizumab plus bevacizumab[120] achieved an ORR of 46% by mRECIST and 50% by RECIST in advanced HCC, respectively. As a result, the later combination was granted breakthrough therapy designation by the FDA[121]. Of note, most of the drugs approved under the accelerated program reported ORR exceeding 30%[122].

**Patient-reported endpoints: Quality of life**

Health-related QOL measures the effect of the disease on an individual's physical, psychological and social functioning and well-being[123]. Regulatory agencies recognize symptomatic improvement as a direct clinical benefit to patients and an important consideration in drug approval[124]. However, unlike OS, the interpretation of QOL is subjective. In HCC, two tools have been proposed to measure QOL: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-HCC18)[125] and the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire[126]. They can be used to evaluate time to symptomatic progression (i.e. time between trial allocation and the occurrence of disease related symptoms according to pre-established scores). QOL was measured in the SHARP trial[7] according to the FHSI-8 questionnaire[127], a reduced version of FACT-Hep, with results that collided with OS. Conversely, the SARA trial[14] reported better global health status with Y-90 when compared to sorafenib based on QLQ-HCC18, which was inconsistent with the primary endpoint of OS. Evaluation of QOL is contingent on when it was assessed during disease progression. Also, significant changes in QOL have been observed across different cultures[128].
Defining and evaluating reliable QOL assessment tools has been established as one of the unmet needs in HCC research by international guidelines[4]. In summary, health-related QOL measures are not ready to support, as single tools, regulatory approval for drugs in HCC.

Conclusions

The current period of drug development in HCC is providing major advancements in the management of this devastating disease. Six drugs have currently shown activity as systemic therapies, which represents an unprecedented revolution for the last 50 years. Novel drugs or combinations strategies are emerging in the field, and thus new tools will be required for the proper assessment of clinical benefits. OS is still the most robust endpoint but the increasing number of treatments available in advanced HCC precludes the use of surrogate endpoints, less vulnerable to subsequent treatments after progression. In this scenario, PFS has shown moderate correlation with OS (R=0.84), and a threshold of HR≤0.6 defines a conservative approach of surrogate endpoint able to capture survival differences in a superiority trial with a high positive predictive value. Two recent studies have been released supporting our threshold of HR ≤ 0.6 for PFS. The first one, an individual-patient data meta-analysis of two RCTs (REACH[21] and REACH-2[25]), showing a significant OS HR with a PFS HR of 0.57[129]. The second one, a phase 3 RCT comparing sorafenib with or without cTACE in advanced HCC, a negative study for its primary endpoint (OS) with a PFS HR of 0.73[130]. Thus, PFS-HR ≤0.6 could be considered a candidate endpoint in phase II and phase III RCTs when subsequent therapies are expected to impact overall outcome. ORR by sensitive criteria (mRECIST) may be useful particularly in single arm phase II trials with proof of concept drugs or in combination studies targeting accelerated approval with a threshold >30%. Finally, the current development of RCTs assessing immune therapies or drug combinations in HCC will certainly evolve the paradigm of drug development and trial design. Particularly of interest will be whether the statements proposed in the present review are confirmed in trials designed with composite primary endpoints, such as OS-PFS for lenvatinib+pembrolizumab vs lenvatinib (NCT03713593) or OS-ORR for atezolizumab+bevacizumab vs sorafenib (NCT03434379).

Key points

- In the last two years four systemic agents (i.e., regorafenib, lenvatinib, cabozantinib and ramucirumab) have shown clinical benefit in the setting of phase III trials and one (i.e., nivolumab) has been granted accelerated approval based on a phase II trial, expanding, thus, the pipeline of effective drugs available in advanced HCC to providers.
- The improvement in the number of effective agents comes at a cost of increased complexity of clinical decision-making, and thus, in the design of future clinical trials.
• OS is still the most robust endpoint in advanced HCC but the increasing number of treatments after progression underscore the need for surrogate endpoints.

• PFS has a moderate correlation at trial level with OS (R=0.84). A conservative minimum surrogate threshold effect of HR ≤0.6 is highly predictive of a significant improvement in OS, whereas HR ranging from 0.6 – 0.7 are uncertain surrogates.

• ORR by sensitive criteria in single arm phase II trials could be a useful tool to prioritize treatments for testing in phase III trials.

References


Figure legends

Figure 1: Median overall survival of treatment modalities assessed in phase III trials for advanced hepatocellular carcinoma.
Treatments with more than one dot represent all the results obtained from different clinical trials testing the same compound. Trials are colored based on whether the final result was positive for superiority (green), negative (red) or positive for non-inferiority (orange) for the primary endpoint (OS). Placebo appears in blue. Relevant inclusion/exclusion criteria that may impact on median OS are: no portal vein invasion [13], no pulmonary metastases [37], sorafenib tolerant [22], MET high [23] and AFP>400ng/ml [25].

Figure 2: Treatment strategy for advanced hepatocellular carcinoma. Adapted from Llovet et al. Nat Rev Clin Oncol 2018[6].
Drugs in green have positive results from phase III trials with a superiority design (sorafenib in the first-line setting and regorafenib, cabozantinib and ramucirumab in the second-line setting). Drugs in orange have positive results from phase III trials with a non-inferiority design (lenvatinib in the first-line setting). Drugs in red have received accelerated approval from the FDA on the basis of promising efficacy results in phase II trials (nivolumab in the second-line setting). Key details of the patient populations are provided. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer (classification); ECOG PS: Eastern Cooperative Oncology Group performance status; EHS: extrahepatic spread; HCV: hepatitis C virus; HR: hazard ratio; mRECIST: modified Response Evaluation Criteria In Solid Tumors; ORR: objective response rate; OS: overall survival.

Figure 3: Correlation between surrogate endpoints (PFS[A] and TTP[B]) and hard endpoint (OS).
Trial-level correlation between endpoints using criteria from the Institute for Quality and Efficiency in Health Care (IQWIG). R and R2 refers to the weighted Pearson coefficient between the HR of OS and the HR of the surrogate endpoint. IQWIG categorizes the strength of the correlation based on the value of R as low (R<0.7), moderate (R>0.7 to R<0.85) and high (R>0.85)[89]. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate (TTP or PFS) and the hard endpoint (OS), respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.
Figure 4: Correlation between surrogate endpoints PFS and TTP.
Trial-level correlation between endpoints. R and R² refer to the weighted Pearson coefficient between the HR of PFS and the HR of TTP. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate TTP and PFS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.

Supplementary Figure 1: Correlation between objective response and OS.
Trial-level correlation between endpoints. R and R² refer to the weighted Pearson coefficient between the HR of OS and the odds ratio of objective response. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the odds ratio for objective response and the HR for OS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.

Tables

Table 1: Phase III trials in advanced hepatocellular carcinoma conducted in the last decade.
Table 2: Studies analyzing associations between radiological response and survival in hepatocellular carcinoma.
Title: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

Authors
Josep M Llovet\textsuperscript{1,2,3}, Robert Montal\textsuperscript{1}, Augusto Villanueva\textsuperscript{2,4}.

Affiliations
\textsuperscript{1}Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
\textsuperscript{2}Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
\textsuperscript{3}Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
\textsuperscript{4}Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Corresponding author
Josep M Llovet, Translational Research in Hepatic Oncology, IDIBAPS-Hospital Clinic, Rosselló 153, 08039, Barcelona, Catalonia, Spain; Tel. 0034-932.279.155; Email address: jmllovet@clinic.cat

Keywords: trial design; liver cancer; systemic therapies; FDA approval.

Electronic word count: 6756.

Number of figures and tables: 4 figures, 2 tables, 1 supplementary figure.

Financial support statement: JML is supported by grants from European Commission Horizon 2020 Program (HEPCAR, proposal number 667273-2), US Department of Defense (CA150272P3), National Cancer Institute (P30 CA196521), Spanish National Health Institute (SAF 2016-76390), Cancer Research UK – Asociación Española Contra el Cáncer (Accelerator Award-HUNTER-A26813), Samuel Waxman Cancer Research Foundation, Generalitat de Catalunya (AGAUR, SGR-1358). AV is supported by U.S. Department of Defense (CA150272P3) and Tisch Cancer Institute (Cancer Center Grant P30 CA196521). RM is supported by a FSEOM – Boehringer Ingelheim grant.

Conflict of interest statement: JML and AV are inventors of a patent for the immune molecular subclass in HCC. Dr Llovet is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb and Ipsen, and consulting fees from Eli Lilly, Bayer HealthCare
Pharmaceuticals, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, Sprink Pharmaceuticals, Nucleix and Cat-Fite pharmaceuticals.

Summary

Hepatocellular carcinoma (HCC) is a relevant cause of cancer-related mortality worldwide. Around half of HCC patients will receive systemic therapies during their life span. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal anti-tumoral efficacy, toxicity, or trials with lack of enrichment strategies. This trend has changed during the period 2016-18, when several compounds such as lenvatinib (in first line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line) showed clinical benefit. These successes came at a cost of increasing the complexity of decision-making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with single active agents has surpassed the threshold of 1 year and the field is facing encouraging outcomes ~2 years with sequential strategies. Overall survival (OS) remains as the main endpoint in phase III investigations, but as in other solid tumors, there is a clear need to define surrogate endpoints that both reliably recapitulate survival benefits and can be assessed prior additional efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to progression (TTP) with OS (R=0.84 and R=0.83, respectively). Nonetheless, significant differences in PFS were only followed by differences in survival in 3 out of 7 phase III studies. In these later cases, the magnitude of benefit for PFS was HR ≤ 0.6, and thus this threshold is herein proposed as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
Introduction

The incidence of hepatocellular carcinoma (HCC) is increasing and will soon surpass one million annual cases worldwide[1]. Up to 80% of HCC patients have concomitant liver cirrhosis, mainly as result of hepatitis B and C virus infection, alcohol abuse or non-alcoholic steatohepatitis in the context of metabolic syndrome[2]. Coexistence of cancer and cirrhosis in HCC is an essential hallmark that has shaped clinical trial design in HCC, as encapsulated in the Barcelona Clinic Liver Cancer (BCLC) algorithm[3,4]. Only 40% of HCC patients are diagnosed at early stages, when potentially curative treatments (i.e. resection, liver transplantation and local ablation) are applicable[4]. As disease progresses, transarterial chemoembolization[5] (for intermediate HCC) and systemic targeted therapies[6] (for advanced HCC) have shown survival benefits. Since sorafenib positive impact in survival[7], at least 10 trials have shown negative results in front-line. In the last 2 years, however, numerous systemic agents have demonstrated clinical benefit in the context of phase III trials. The fact that six drugs are currently effective and/or approved by the Food and Drug Administration (FDA) for the management of advanced HCC poses a challenge for assessing novel strategies in this arena in terms of trial design. Overall survival (OS) is an unquestionable, unbiased primary endpoint in oncology and in all randomized studies testing systemic therapies in first and second line in advanced HCC[7-27]. However, other solid tumors have identified surrogate endpoints of survival that led to accelerated and regular approval, notably objective response rate (ORR) and progression free survival (PFS)[28,29]. These endpoints are aimed to recapitulate survival benefits with the advantage of being assessed prior additional efficacious drugs are administered. By thoroughly analyzing the past experience since sorafenib approval, we have assessed the correlation between surrogate endpoint such PFS, time to progression (TTP) and ORR with clinically meaningful improvements in OS in 21 reported phase III studies[7-27]. Based on this analysis and a conservative approach to define surrogates of OS in HCC, we propose PFS with a threshold of HR≤ 0.6 as reliable surrogate with solid positive predictive value, whereas the threshold of HR=0.6-0.7 -despite leading to positive statistical results- is defined as clinically uncertain in terms of capturing true advantages in OS. In addition, we revisit the correlation between ORR by mRECIST and OS and define again that ORR is an independent predictor of OS at early, intermediate and advanced stages, meaning that responders survive significantly longer. Nonetheless, ORR is still a suboptimal tool as surrogate due to the low sensitivity in capturing those patients that benefit from a given drug. Ultimately, we envision providing a historical perspective of HCC trial design, which are the lessons to be learned, and how to maximize clinical trials success in the near future.

Overview of phase III and practice-changing phase II trials reported during the last 10 years

Current estimates suggest that around 50% of HCC patients will receive systemic therapies at one time point or another during their lifespan [2,4,30]. Several trials have tried to show survival
benefits of systemic agents in advanced disease, a traditionally challenging setting due to the limit
efficacy and high toxicity of conventional systemic chemotherapy[16–18,31]. Randomized studies
also failed to prove any clinical efficacy for anti-estrogen therapies[32]. In 2008, the landmark
SHARP trial assessing the multi-tyrosine kinase inhibitor sorafenib (VEGFRs, PDGFRs, RAF and
KIT) was the first to significantly expand survival (hazard ratio (HR) of 0.89) with manageable
adverse events[7]. Similar efficacy was demonstrated in the phase III trial testing sorafenib in Asian
patients[8]. These successful results helped established contemporary concepts in trial design that
have been implemented in phase III trials over the succeeding years (Table 1 and Figure 1)[33].
The main concepts implemented in these trials are: a) selection of patients with well-preserved liver
function (i.e., Child-Pugh A class) to minimize the competing risk of liver failure and death as a
result of the natural history of cirrhosis; b) restriction of the investigational niches to those stages
with unmet medical needs such as advanced stage (BCLC C), or intermediate stage (BCLC B)
progressing after TACE in case of systemic treatments or adjuvant setting after resection/local
ablation; c) use of OS as the cornerstone primary endpoint to assess efficacy in advanced stages,
and d) use of critical prognostic factors as tools for stratification prior randomization based upon
ECOG 0 vs 1, macrovascular invasion, extrahepatic spread, and alpha-fetoprotein (AFP) levels
(>400 ng/ml). Etiology is not considered a prognostic factor, but needs to be incorporated when
testing sorafenib, since it has been demonstrated to be a predictor of response for this drug, at the
same level than absence of extrahepatic spread and low neutrophil-to-lymphocyte ratio[34].

In this context, new treatment modalities emerged to challenge sorafenib in first-line or
placebo in second-line. These include brivanib (VEGFRs and FGFRs)[10,19], sunitinib (VEGFRs,
PDGFRs and KIT)[9], lenvatinib (VEGFRs and PDGFRs)[11], erlotinib (EGFR) in combination to
sorafenib[12], everolimus (mTOR)[20], tivantinib (MET)[23], doxorubicin loaded nanoparticles[27]
and ADI-PEG 20 (arginine deaminase enzyme)[26] (Table 1). All of them had disappointing results
and it was not until 2016 that the RESORCE study led to the first positive phase III trial in advanced
HCC for nearly a decade. Regorafenib (VEGFRs, PDGFRs, KIT and Tie2) improved OS compared
to placebo from 7.8 to 10.6 months in patients who progressed and were tolerant to sorafenib[22].
Notably, OS from starting sorafenib follow by regorafenib was 26 months compared to 19 months
for sorafenib followed by placebo for patients with advanced HCC [35]. Besides regorafenib, other
phase III clinical trials have recently improved OS in second-line when compared to placebo: The
CELESTIAL study, showing median OS of 10.2 months with cabozantinib (VEGFRs, MET and
AXL) vs 8 months with placebo[24]; and the REACH-2 study, where ramucirumab (VEGFR2
monoclonal antibody) provided a median OS of 8.5 months in patients with AFP equal or higher
than 400 ng/ml vs 7.3 months with placebo[21,25]. AFP is well-known for its independent prognostic
capacity in HCC[36]. As such, REACH-2 becomes the first positive phase III trial in a biomarker-
driven population of HCC patients. In parallel, lenvatinib (VEGFRs, FGFRs, RET, KIT and
PDGFRa) has become an option in frontline after the positive result of the non-inferiority REFLECT
study[13]. In contrast, three phase III trials testing internal radiation with Y-90 for advanced HCC, either as single treatment [SARAH][14] and SIRveNIB[15]] or in combination Y-90 plus sorafenib[37] did not meet the primary endpoint of improved OS compared to sorafenib. As a result, Y-90 is discouraged for the management of advanced HCC in the recent EASL guidelines[4].

Finally, the FDA has granted accelerated approval to the immune checkpoint inhibitor nivolumab (monoclonal antibody against PD1) in second-line after a large phase II single-arm trial showing promising ORR of 14% by RECIST (responses lasting more than 12 months in 55% of cases)[38,39]. Pembrolizumab has recently shown an ORR of 17% and median OS of 12.9 months in the second-line setting[40]. The revolution of immune therapies that has changed the paradigm of treatment in oncology is now finding its way in HCC, with ongoing phase III in both first- (NCT02576509, NCT03298451, NCT03434379, NCT03713593) and second-line (NCT02702401) targeting key mediators of the anti-cancer immune response (e.g., PD1, PDL1, CTLA4, LAG3). Overall, these successful results have amplified the number of effective drugs available to clinicians for the management of advanced HCC (Figure 2). New studies will be crucial to ascertain the most efficient way to utilize these drugs and maximize clinical benefit.

**Reasons for positive/negative results in phase III investigations**

**Negative phase III clinical trials**

Until 2016, sorafenib was the only systemic agent able to significantly increase survival in patients with advanced HCC[7]. This was despite numerous attempts to improve, or parallel (i.e., non-inferiority trials), its efficacy and develop new second-line therapies in the context of phase III trials (Table 1). Until then none of the 8 randomized clinical trials (RCTs) testing systemic treatments (vs sorafenib in front line[9–12,17] or placebo in second-line[19–21]) was able to achieve positive results. Nowadays, 6 of 21 (29%) trials have been able to meet the primary endpoint and potentially change the standard of care. This success rate is lower than in other tumor types, with reported success rate of 37%[41], and resonates with the difficulties of developing effective drugs in HCC. Negative HCC trials enrolled a total of 8,604 patients and consumed a significant amount of resources. Failed drugs include linifanib[11], erlotinib[12], brivanib[10,19], sunitinib[9], doxorubicin[17,27], everolimus[20], tivantinib[23], ADI-PEG 20[26] and radioembolization with Y-90[14,15] (Table 1). These drugs have different molecular targets, mechanisms of action, and include various treatment modalities (pharmacological vs radiation-based). Thus, it is likely that multiple reasons contributed to their failure, but we will dissect three key factors, reviewed in [42]: a) limited anti-tumoral efficacy (or biological activity), b) significant toxicity, and c) lack of effective enrichment strategies for patient enrollment.

*Limited anti-tumoral efficacy (or biological activity)*
The first factor relates to limited anti-tumoral activity of the drug as per its main molecular targets. This implies that either they have a marginal role in HCC progression, or their selective inhibition is insufficient to induce a significant clinical benefit. For instance, evidence from murine models demonstrated how aberrant activation of MTOR signaling promotes liver cancer[43], and how its selective abrogation has anti-tumoral effects in xenografts[44]. In human HCC, MTOR pathway is deregulated in up to 45% of samples[44,45], and yet, the phase III trial testing everolimus was unable to improve survival compared to placebo in second line with a HR for OS of 1.05[20]. Data in phase II already suggested a modest median survival of 8.4 months[46] associated to marginal response rates. Also, the companion biomarker study for the phase III trial failed to find any robust predictive biomarker of response to everolimus[47]. Altogether, these data suggest that MTOR inhibition has no anti-tumoral activity in advanced HCC. Other drugs potentially falling under this category include the EGFR inhibitor erlotinib[12], and the FGFR2/VEGFR inhibitor brivanib[10,19]. Limited efficacy can also be claimed for Y-90 resin microsphere treatment as a superior alternative to sorafenib. The phase III trials reported[14,15] were negative with a HR for OS of 1.1. It is important to note that failure to demonstrate superiority does not mean similar efficacy, which requires an ad hoc trial design for non-inferiority or equivalence, a concept that will be further discussed in this review[48].

**Drug toxicity**

The second reason is significant drug toxicity, which is relevant in cirrhotic patients since liver dysfunction decreases the threshold for severe adverse effects. The best example is sunitinib[49], that despite having a molecular target profile similar to sorafenib, it was unable to improve survival when compared in frontline[9]. The trial was prematurely terminated due to futility and safety concerns affecting sunitinib. Median OS for sunitinib was 7.9 months, compared to the 10.2 with sorafenib (HR of 1.3). Treatment-related deaths occurred in 3.2% and 0.4% of patients receiving sunitinib and sorafenib, respectively. When this trial was conducted, sunitinib was already FDA approved for advanced kidney cancer and gastrointestinal stromal tumors, where toxicity was not a major clinical issue. However, in patients with underlying liver disease the toxicity of sunitinib was severe enough to obscure any beneficial anti-tumoral efficacy. Sunitinib has a higher inhibitory potency than sorafenib, particularly regarding its anti-angiogenic activity via VEGFR and PDGFR Inhibition[50]. Angiogenesis is critical during liver fibrogenesis[51], so the strong and sustained anti-angiogenic effect achieved with sunitinib seems detrimental, favoring liver failure. Previous phase II trials testing sunitinib in HCC offer additional insights into the hepatic toxicity of this drug[52–54], including up to 4/37 (11%) treatment-related deaths[54]. An adequate identification of toxicity signals at this stage could help mitigate this problem. Another example is the VEGFR/PDGFR inhibitor linifanib, tested in frontline versus sorafenib[11]. This trial was early terminated based on futility (median OS for linifanib and sorafenib were 9.1 and 9.8 months), but grade 3-4 adverse events were significantly more frequent in linifanib than in sorafenib, including hypertension (21% vs
11%) and hepatic encephalopathy (7% vs 3%). Besides the negative effect of toxicity in clinical outcomes, there is a subtler effect of non-lethal toxicity as it associates with dose reductions, which could also decrease antitumor potency.

**Lack of trial enrichment strategies**

A third reason for clinical trial failure is lack of effective enrichment strategies for patient enrollment based on predicted biomarkers of response. Trial enrichment in oncology is closely linked to the concept of oncogene addiction. This term describes those molecular alterations, generally DNA mutations or chromosomal aberrations, required for cancer cell proliferation and survival[55]. There are numerous examples in oncology of survival benefits after a clinical trial testing a drug only in those patients with mutations in its target[56] (e.g., ALK rearrangements in lung cancer and response to crizotinib[57]). Only 2/21 (10%) phase III trials in advanced HCC incorporated patient enrichment, likely due to: a) limited access to tumor tissue in patients already diagnosed by noninvasive criteria; and b) few druggable targets among the most common genetic alterations in HCC[58,59]. In fact, the most common mutations in HCC (TERT promoter, CTNNB1, TP53, AXIN1, ARID1A and ARID1B) are untargetable[2,60]. One of them evaluated tivantinib versus placebo in second line in patients with high expression of MET assessed with immunohistochemistry[23]. This trial was based on a post-hoc analysis of 37 patients from a previous phase 2 trial[61] and failed to meet its primary endpoint with a HR for OS of 0.97. Arguably, the signal in the phase 2 trial was weak, but most important, recent data questions the specificity of tivantinib as a MET inhibitor[62]. It was also thought that MET was a prognostic factor, but: the median survival of 9.1 months for the placebo arm in MET-high patients in second-line challenges this concept[23]. The second trial tested the VEGFR2 monoclonal antibody ramucirumab versus placebo in second line (i.e. REACH-2) in patients with AFP higher than 400 ng/mL, and showed a significant improvement in OS versus placebo (HR of 0.71[25]). A difference with the tivantinib case is that the rationale for REACH-2 came from a post hoc analysis of the negative phase III trial in all-comers (i.e., REACH[21]) which enrolled 565 patients. This showed a robust p of interaction favoring ramucirumab in patients with high AFP of 0.02. AFP is a well-known poor prognostic marker[36,47]; highly expressed in tumors with a supposed progenitor cell origin[63], but it does not provide a neat link between any specific driver oncogenic event (i.e., structural DNA alteration or signaling pathway) and ramucirumab’s main molecular target. Experimental evidence identifies VEGFR2 as a marker of hepatic progenitors[64], which could hypothetically explain the efficacy of ramucirumab in tumors with high AFP.

**Positive phase III clinical trials**

Successful drugs in frontline include sorafenib and lenvatinib, whereas regorafenib, cabozantinib, and ramucirumab in patients with high AFP demonstrated efficacy in second line (Table 1 and Figure 2). The PD1 inhibitor nivolumab has shown promising results in phase II with an
ORR of 14% by RECIST (18% by mRECIST) and a median OS of 15.6 months [38,65], which granted its accelerated approval by the FDA. Another immune-based therapy - pembrolizumab-reported similar ORR (17%) but lower median OS (12.9 months[40]). Data from phase III trials in first-line (nivolumab vs sorafenib) and in second-line (pembrolizumab vs placebo) will be critical to fully recommend these immune-based therapies in clinical practice guidelines[4]. Since the strength of evidence so far comes from phase II data, current EASL guidelines just posed a weak recommendation for nivolumab[4].

The reasons for trial failure provide the best clues for the qualities of a drug to be successful in HCC, which essentially are: a) adequate clinical trial design with an emphasis on selection criteria and robust endpoints; b) a fine balance between drug efficacy and toxicity; and c) a proper interpretation of efficacy and toxicity signals in phase II trials. Sorafenib epitomizes these qualities, and to certain extent, the design principles implemented in the pivotal SHARP trial[7] were adopted as best-practices for design in subsequent studies[33]. The target population must include patients with well-preserved liver function (i.e., Child-Pugh A with compensated liver disease) to avoid competing risks from deaths due to progression of the liver disease, and to minimize drug toxicity. Also, patients need to be fit enough to tolerate the drug and with a life expectancy of at least 3 months, which can be reasonably guaranteed by enrolling patients with ECOG performance status test (PST) of 0-1. It is paramount to enroll patients at the same clinical stage as per the BCLC classification[4,66]. The SHARP trial was instrumental to eradicate the misleading concept of ‘unresectable’ HCC when conducting HCC trials. This concept included a heterogeneous population of patients at intermediate (BCLC-B) and advanced (BCLC-C) stages[67], which imposed significant bias when interpreting trial results. In addition to the same clinical stage, patients need to be adequately stratified for known HCC prognostic factors and geographic region.

Regarding patient’s selection, the success of the REACH-2 trial underscores the importance of properly interpreting post hoc analysis. The pooled analysis of REACH and REACH-2 assessing ramucirumab in those patients with AFP > 400 ng/mL further confirms a significant and clinically meaningful benefit of ramucirumab vs placebo in second-line (median survival 8.1 vs 5 months; HR=0.694)[25]. The rationale to enrich trials based on predicted oncogene addiction is two-fold: first, to maximize anti-tumoral response by perturbing the cancer drivers active in a given patient, and second, to spare unnecessary toxicity in those patients without the oncogene addiction. HCC has few druggable targets among the most frequent driver mutations, but a recent proof-of-concept trial reinforces the validity of this approach to explore treatment response[68]. A screening of 1,318 HCC patients allowed enrolling 54 cases with RAS mutations (4.4%) detected using circulating tumor DNA (ctDNA) in a phase II trial testing the combination of sorafenib with the MEK inhibitor refametinib[68]. Mutation analysis of ctDNA is feasible in HCC[69] and facilitates screening of large populations. Other potential druggable oncogenic alterations in HCC include high-level DNA amplifications of FGF19[70,71] or VEGFA[70,72]. Phase II clinical trials are currently exploring
selective inhibition of these candidate oncogene addition loops[73]. There is also increasing interest in developing biomarkers to identify the 20% of patients who respond to immune-based therapies, who show outstanding OS. The use of PD-L1 staining seems irrelevant in HCC[38], and other potential biomarkers such as tumor mutational burden (TMB)|[74] or the HCC immune class[75] are under investigation. To facilitate the implementation of biomarker-based clinical trials in HCC, it is essential to enforce mandatory tissue collection in all clinical trials testing new compounds[4]. In this regard, the impact of intratumor heterogeneity in single-biopsy predictions is still debated despite recent studies have shown that driver gene mutations are common between different regions of the tumor[76,77].

Traditionally, new therapies were compared with standard of care or placebo to demonstrate greater efficacy of the new drug. Despite this is the recommended trial design practice in HCC|4,33], some studies after SHARP used non-inferiority designs to challenge sorafenib in first-line. The hypothesis in non-inferiority trials is that the new compound is not substantially worse than the current standard, as opposed to equivalence trials, which are designed to demonstrate that the experimental treatment is neither worse not better than the standard therapy[78]. Non-inferiority trials are required to claim similar efficacy as opposed to assuming it from a negative superiority trial, as previously explained for the Y-90 trials. The non-inferiority trial scenario in HCC is extensively described elsewhere|42], and caveats include the need for larger sample sizes and a very small window of opportunity, as defined by the tight non-inferiority margins. For instance, the BRISK-FL trial was designed to demonstrate non-inferiority of brivanib compared to sorafenib in first line|10]. The trial assumptions set the upper limit of the 95% confidence interval of HR for OS to 1.08. To call non-inferiority, the HR could cross 1, but the upper boundary needed to fall between 1 and 1.08. This threshold is very stringent and can be interpreted as the requirement to demonstrate a robust non-significant trend towards superiority for the new drug. The value proposed by FDA has been calculated based upon capturing at least >60% of the survival benefit obtained with sorafenib|13]. The BRISK-FL trial did not meet this endpoint since the HR confidence interval limits for OS were 0.94 and 1.23. The concept of non-inferiority trials introduces other considerations in treatment recommendations such as toxicity or cost, which will surely contribute to frame the landscape of systemic therapies in HCC.

**Hard and surrogate endpoints: implications in clinical trial design**

The overarching goal of oncological treatments is to allow patients to live longer and better lives than they would do without treatment|79]. Thus, clinical research needs to unequivocally demonstrate statistically and clinically meaningful improvements of the experimental arm over the standard of care. Three types of endpoints have been defined: 1. Hard endpoints, such as overall survival and cancer-specific survival; 2. Surrogate endpoints such as PFS, TTP and ORR, and 3. Patient reported endpoints, such as quality of life (QOL).
Overall survival

This hard endpoint quantifies the time between random trial allocation and death, whatever the cause. Since is not subject to investigator bias, OS has been traditionally recommended by international HCC guidelines as the primary endpoint for randomized phase III trials testing new therapies[80]. In fact, all regular FDA drug approvals in advanced HCC were based upon improvements in OS [7,22]. Cancer-specific survival, where only deaths due to cancer are considered and noncancer-related deaths are censored, is more difficult to assess in conventional trial settings. Deaths due to competing risks, such as liver failure, require a subjective interpretation by the investigator, and thus are more prone to bias[33].

What is the magnitude of benefit to define it as clinically meaningful? This is a controversial topic, highly dependent on the expected outcome for the target population, with confronted opinions between patients, providers, regulatory agencies and health insurers [81,82]. In HCC, there is no consensus on what absolute survival benefit (or the magnitude of benefit in OS as per HR) to be defined as clinically relevant. Reported thresholds of OS with HR<0.8 are also sound for capturing the benefit of patients in advanced HCC trials[83]. An unwritten rule among experts estimate that in advanced HCC scenario, where natural outcome (placebo arm) is estimated to be of around 8 months, absolute gains beyond 2 months are considered clinically relevant, while those below 1 months are not.

Survival has some limitations as a sole endpoint in cancer research. First, it might require a long follow-up time to capture enough events due to significant improvement in median OS in the experimental arm[35]. This negatively impacts feasibility and delays access to patients to highly effective drugs. Second, it can be affected by sequential therapies received after tumor progression (post-progression survival), such as for instance regorafenib after a first-line therapy. This might involve one third of patients in recent phase III trials[13]. In this context, validation of surrogate endpoints of OS is paramount to facilitate trial execution and favor a quick deployment of effective drugs in routine clinical conditions.

Surrogate endpoints: PFS, TTP and ORR

Ideally, significant improvement in OS is preferred, but many drugs have been approved based on their ability to improve other less robust endpoints, termed surrogates (i.e., TTP, PFS and ORR). These are outcomes not inherently meaningful from the clinical standpoint, but thought to accurately predict hard outcomes such as OS[84]. The development of surrogate endpoints became a necessity in clinical trials in cardiology, where the long time to accumulate enough events for a hard endpoint made most studies unfeasible. Use of surrogate endpoints is becoming a need in oncology where effective post-progression therapies are available.
Accelerated approval based upon surrogate endpoints is becoming the most relevant path for cancer drug regulatory approval in the US. Between 2009 and 2014, the FDA approved 83 drugs in oncology, 66% of them on the basis of surrogate endpoints[85]. The FDA's accelerated approval program was introduced in 1992 as a social compromise during the worse years of the HIV epidemic to expedite access to agents for life-threatening conditions based on surrogate endpoints. The program included a "safety net" that required the manufacturer to conduct post-marketing studies and confirm the efficacy of the drug using hard endpoints[86]. A recent analysis of approved drugs during the period 1992-2017 led to the following conclusions[28]: a) Accelerated approval was granted for 93 indications, ORR being the most common surrogate endpoint used (87% of cases), b) Among drugs approved through this path, 55% were ultimately confirmed for regular approval, 5% of indications were withdrawn (e.g., bevacizumab in metastatic breast cancer[87]), whereas in others the process has not been concluded.

Despite the increasing importance of surrogate endpoints in oncology, they have two main limitations. First, since they usually rely on the radiological definition of tumor progression or response, they are vulnerable to interpretation bias. This can be minimized by using central radiology reviews and a designated adjudicator of response. Second, and more important, in order to be reliable, they require validation as credible predictors of OS[84]. Validation of surrogate endpoints can be conducted at the individual- or trial-levels[88]. While validation of individual-level surrogacy requires individual patient data from at least one clinical trial, trial-level surrogacy uses assembled data from multiple trials. The Institute for Quality and Efficiency in Health Care has proposed a set of criteria to quantify the association between a surrogate and hard endpoint, which includes low (R<0.7), moderate (R=0.7 to R<0.85) and high correlation (R>0.85)[89]. R refers to the weighted Pearson coefficient between HR of OS and HR of the surrogate endpoint. Alternative methods to study this correlation have been reported[90]. A systematic review and meta-analysis of trial-level surrogate endpoints (PFS, TTP and ORR) for OS in oncology including 36 articles and 352 clinical trials found low, moderate and high correlation with OS in 52%, 25% and 23% of surrogate endpoints, respectively[84].

In order to explore the concept of surrogate endpoints recapitulating OS in advanced HCC we have identified 21 RCTs assessing systemic therapies with or without loco-regional therapies in advanced HCC (12 in first-line and 9 in second-line) (Table 1) published between 2008 and 2018 through a MEDLINE search via PubMed using the keywords "advanced hepatocellular carcinoma". Results were limited to "clinical trial, phase III". Trials recently presented at international meetings (2016-2018) were also included despite the full manuscript is not yet available. For each trial, data on sample size, radiological response, TTP and OS were collected. TTP and OS were determined in terms of hazard ratio (HR) using published data (values less than 1 denotes a favourable result in the experimental group). In addition, ORR was established with odds ratio calculated from the published radiological response (values greater than 1 denotes a favourable result in the
experimental group). For the purpose of the trial-level analysis, we first assessed the overall correlation between PFS and OS (R=0.84; R²=0.71) (Figure 3A), and then the correlation of TTP and OS (R=0.83; R²=0.69) (Figure 3B). Afterwards, we established a conservative threshold of positive predictive value for PFS since this is the most documented surrogate time-to-event endpoint in oncology, and the one showing a higher correlation with OS[84]. Finally, we explored the correlation between ORR assessed as per mRECIST and survival in early, intermediate and advanced HCC.

**Progression-free survival**

PFS is a composite endpoint of two variables: death and evidence of radiological progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. International guidelines initially discouraged this endpoint in HCC due to the competing risk of dying due to progressed liver dysfunction despite a relevant anti-tumoral benefit[33]. However, this limitation has been mitigated since most trials in HCC have adopted restrictive inclusion criteria in terms of liver function (i.e., Child-Pugh A without decompensation). In this scenario, the likelihood of death as a result of liver decompensation (i.e., gastrointestinal bleeding, encephalopathy or ascites and spontaneous peritonitis) is 5% at one year[93]. When we evaluate the association between PFS and OS in HCC phase III trials, we observe a moderate Pearson correlation (R) of 0.84 (Figure 3A). This figure falls in the upper boundary of a moderate correlation (R between 0.7 and 0.85). When specifically analyzing the positive predictive value of theoretical thresholds of PFS correlating with OS, only 3/7 PFS reported a HR ≤0.6 that was significantly associated with a positive survival clinical benefit (in all cases with a HR for OS < 0.8). Conversely, those four studies reporting a positive PFS with a HR between 0.6-0.8 were associated with no significant survival benefits (HR for OS between 0.87 and 1.05) (Figure 3A). In our study, according to the linear regression equation obtained [log HR\textsubscript{OS} = 0.072 + 0.487 x log HR\textsubscript{PFS}], a threshold of PFS HR=0.6 (representing a 40% risk reduction) will decrease ~17% the risk of OS (OS HR=0.83) (see Figure 3A). In summary, a moderate correlation has been established between PFS and OS in 21 RCTs in advanced HCC. A value of HR ≤0.6 is proposed as surrogate threshold effect [94], and is likely to predict a clinically meaningful improvement in OS. It is worth to mention though that this rule is supported mainly by positive trials in the second-line setting comparing active drugs vs placebo. We assume that such association is retained in front-line comparing two active drugs, but recommendation in that setting should be tempered due to the lack of confirmatory data.

**Time to progression**

This endpoint quantifies the time between trial allocation and radiological progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. Deaths are censored as non-radiological progressions at the time of death or at an earlier visit, with a cause-specific hazard, representing informative censoring. Symmetric repeated radiological measurements every 6-8
weeks are required to avoid missing moderate differences between treatment groups[33]. This recommendation was not followed in the SiRveNIB[15], SARAH[14] and ADI-PEG 20[26] trials.

To delineate the adequacy of TTP as a surrogate of OS in HCC we conducted also a trial-level meta-analysis to evaluate the correlation between TTP and OS in 21 RCTs (Figure 3B). The Pearson correlation (R) was 0.83, which indicates a moderate association according to the IQWIG guidelines[84]. In 10 phase III trials there was a significant difference in TTP in favor of the investigational arm. However, these positive results in TTP were not followed by superiority in OS in 5 (60%) trials. Brivanib[19] and ramucirumab[21] in second-line showed efficacy as per TTP (HR=0.56 and 0.59, respectively), while not significantly improving the hard endpoint of OS (HR=0.89 and 0.87, respectively). Lenvatinib[13] in first-line versus sorafenib also showed significant differences in TTP favoring lenvatinib (HR 0.63), without showing superiority for OS (HR=0.92). This trial was positive since it was designed for non-inferiority (upper 95% CI lower than 1.08). Finally, linifanib[11] and hepatic infusion arterial chemotherapy (HAIC)[18] in first-line failed to show any benefit in terms of OS (HR=1.05 and 1.01, respectively) even though there was a clear benefit when measuring TTP (HR=0.76 and 0.65, respectively). These results do not support the initial recommendation after the SHARP trial of using TTP as the optimal surrogate endpoint[33] in phase 2 trials, and reinforce the need for accurate evaluation of surrogacy in clinical trials. Based on the linear regression model obtained [\( \log \text{HR}_{\text{OS}} = 0.083 + 0.491 \times \log \text{HR}_{\text{TTP}} \)], we can extrapolate that a therapy producing a 40% risk reduction in TTP will yield an estimated \( \sim 16\% \) risk reduction in OS (HR=0.84) (see Figure 3B). Moreover, in order to directly compare the performance of PFS and TTP, we analyzed the correlation between both surrogate endpoints, obtaining a Pearson correlation (R) of 0.99 (Figure 4). Thus, in the modern era of HCC trial design, with minimal cirrhosis-related deaths (due to the inclusion of Child-Pugh A), there is a strong correlation between both endpoints. In fact, when we inferred the non-reported PFS HR of SHARP and AP trials according to the linear equation obtained comparing both surrogate endpoints [\( \log \text{HR}_{\text{PFS}} = 0.014 + 0.927 \times \log \text{HR}_{\text{TTP}} \)], the HRs values are close to 0.60, just at the previously proposed minimum threshold.

There are two other considerations regarding this endpoint. First, not all types of tumor progression may have the same clinical meaning. Recent data also suggest that TTP may capture heterogeneous features, with essentially two types of progression at advanced stages[95,96]. In particular, survival after progression is significantly worse for patients who develop a new extrahepatic lesion and/or vascular invasion (median OS = 7.1 months) compared to those who progress due to the growth of existing intrahepatic extrahepatic lesions or the development of a new intrahepatic lesion (median OS = 14.9 months). Second, factors including evaluation bias, trial attrition or informative censoring may weaken the association between the TTP and OS [29]. Finally, prolonged exposure to a given therapy might lead to a phenotypic change in tumors, thus, offsetting any initial advantage from the treatment captured by the surrogate endpoint[97].
**Objective response rate**

Tumor response in oncology trials is typically measured using the Response Evaluation Criteria in Solid Tumors (RECIST)\(^{91}\). These criteria standardize methods for converting radiological observations into a quantitative and statistically tractable framework to define tumor response (i.e., a 30% decrease in the diameter of target lesion). ORR is the percentage of patients who achieve an objective tumor response. Disease control rate (DCR) is the combination of ORR and stable disease, but it has two disadvantages that limit its adoption for regulatory approval: a) the definition of duration of stable disease varies between studies; and b) stable disease can reflect inherent characteristics of the tumor rather than treatment efficacy.

The RECIST criteria were originally developed to evaluate cytotoxic agents. The generalization of targeted therapies has challenged this simplistic approach that relies on tumor shrinkage to indicate clinical efficacy. Sorafenib was associated with only 2-3% of ORR, despite providing clear survival benefits\(^{7,8}\). Given the poor correlation between tumor response assessed with conventional tools and OS, a group of experts convened by the American Association for the Study of Liver Diseases (AASLD) proposed specific amendments to standard RECIST\(^{33}\). Further description of response and progression resulted in the criteria named modified RECIST (mRECIST), which ultimately incorporates the concept of viable tumor defined as the portions of tumor showing arterial enhancement\(^{92}\). The mRECIST criteria in HCC have improved the sensitivity to quantify tumor response with targeted therapies: ORR of 9-17% with sorafenib\(^{10,13,18}\), 10-12% with brivanib\(^{10,19}\), 11% with regorafenib\(^{22}\) and 24% with lenvatinib\(^{13}\). Retrospective studies have consistently demonstrated that patients who achieved an objective response on sorafenib had a longer survival than non-responders\(^{98-100}\). Recently, data from double-blind randomized trials assessing brivanib and nintedanib further validated this association \(^{101,102}\). Thus, the association between tumor response and improved OS in HCC patients at advanced stages complement what was already knew in patients at early and intermediate stages treated with loco-regional therapies\(^{103-109}\)\(^{[Table 2]}\).

When we evaluate the trial-level correlation between ORR and OS (Supplementary Figure 1), the R weighted Pearson coefficient obtained is 0.54. This is significantly lower than the correlation obtained with PFS/TTP and OS as depicted in Figure 3. There are two reasons for this: one is inherent to the use of odds ratio instead of hazard ratio to compare differences in ORR. The accuracy of odds ratio decreases for low values of ORRs. The second reason is that only a small proportion of patients within these trials achieved ORR (~10-20%), which is, in fact, the event that correlates with better survival\(^{101}\). A direct comparison between RECIST and mRECIST for OS surrogacy through an independent meta-analysis of trials using either criteria would be ideal to define the role of ORR to predict OS in advanced HCC. This will also help determine the best tool to evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response...
data using mRECIST, we did not sub-analyze this endpoint according to the tool used to evaluate response.

Some other questions remain unanswered. As observed in other solid tumors treated with efficacious targeted therapies[110-112], the reported rates of responders are still suboptimal to estimate the maximum number of patients who would benefit from the treatment. In addition, the duration of response might be more clinically relevant than the extent of tumor reduction. Finally, the strategy to evaluate response might require a thoughtful revision when assessing immunotherapies. As shown in melanoma patients treated with checkpoint inhibitors, standard RECIST may not provide a reliable assessment of antitumor efficacy[113]. In fact, response to immunotherapy may take longer compared to other agents and can even falsely mirror criteria for progression (i.e., pseudo-progression)[114]. Immune-related response criteria have been developed[115,116], including the concept of “confirmation of progression” by a second scan obtained at least 4 weeks after progressive disease has been registered.

Despite all the challenges that evaluation of tumor response face in oncology, and particularly in HCC, the importance of ORR as a surrogate endpoint is recognized by regulatory agencies and frequently used for accelerated drug approval. This was the case of nivolumab, approved in second-line based on an ORR of 18% by mRECIST and 14% by RECIST [38,39]. Remarkably, objective response to nivolumab has been associated with prolonged OS[65]. Overall, the fact that a high ORR in phase II trials was considered a robust criterion for drug approval[117], and further success in phase III trials[118], indicates that ORR should be considered as a primary endpoint for single-arm phase II studies. Related to this, early clinical trials are showing promising results with combinations of checkpoint inhibitors and targeted therapies, as measured by ORR. Lenvatinib plus pembrolizumab[119] and atezolizumab plus bevacizumab[120] achieved an ORR of 46% by mRECIST and 50% by RECIST in advanced HCC, respectively. As a result, the later combination was granted breakthrough therapy designation by the FDA[121]. Of note, most of the drugs approved under the accelerated program reported ORR exceeding 30%[122].

**Patient-reported endpoints: Quality of life**

Health-related QOL measures the effect of the disease on an individual's physical, psychological and social functioning and well-being[123]. Regulatory agencies recognize symptomatic improvement as a direct clinical benefit to patients and an important consideration in drug approval[124]. However, unlike OS, the interpretation of QOL is subjective. In HCC, two tools have been proposed to measure QOL: the European Organization for Research and Treatment of Cancer Quality of Live Questionnaire (EORTC QLQ-HCC18)[125] and the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire[126]. They can be used to evaluate time to symptomatic progression (i.e. time between trial allocation and the occurrence of disease related symptoms according to preestablished scores). QOL was measured in the SHARP trial[7]
according to the FHSI-8 questionnaire[127], a reduced version of FACT-Hep, with results that collided with OS. Conversely, the SARAH trial[14] reported better global health status with Y-90 when compared to sorafenib based on QLQ-HCC18, which was inconsistent with the primary endpoint of OS. Evaluation of QOL is contingent on when it was assessed during disease progression. Also, significant changes in QOL have been observed across different cultures[128]. Defining and evaluating reliable QOL assessment tools has been established as one of the unmet needs in HCC research by international guidelines[4]. In summary, health-related QOL measures are not ready to support, as single tools, regulatory approval for drugs in HCC.

Conclusions

The current period of drug development in HCC is providing major advancements in the management of this devastating disease. Six drugs have currently shown activity as systemic therapies, which represents an unprecedented revolution for the last 50 years. Novel drugs or combinations strategies are emerging in the field, and thus new tools will be required for the proper assessment of clinical benefits. OS is still the most robust endpoint but the increasing number of treatments available in advanced HCC precludes the use of surrogate endpoints, less vulnerable to subsequent treatments after progression. In this scenario, PFS has shown moderate correlation with OS (R=0.84), and a threshold of HR<0.6 defines a conservative approach of surrogate endpoint able to capture survival differences in a superiority trial with a high positive predictive value. Two recent studies have been released supporting our threshold of HR ≤ 0.6 for PFS. The first one, an individual-patient data meta-analysis of two RCTs (REACH[21] and REACH-2[25]), showing a significant OS HR with a PFS HR of 0.57[129]. The second one, a phase 3 RCT comparing sorafenib with or without cTACE in advanced HCC, a negative study for its primary endpoint (OS) with a PFS HR of 0.73[130]. Thus, PFS-HR ≤0.6 could be considered a candidate endpoint in phase II and phase III RCTs when subsequent therapies are expected to impact overall outcome. ORR by sensitive criteria (mRECIST) may be useful particularly in single arm phase II trials with proof of concept drugs or in combination studies targeting accelerated approval with a threshold >30%. Finally, the current development of RCTs assessing immune therapies or drug combinations in HCC will certainly evolve the paradigm of drug development and trial design. Particularly of interest will be whether the statements proposed in the present review are confirmed in trials designed with composite primary endpoints, such as OS-PFS for lenvatinib+pembrolizumab vs lenvatinib (NCT03713593) or OS-ORR for atezolizumab+bevacizumab vs sorafenib (NCT03434379).

Key points

- In the last two years four systemic agents (i.e., regorafenib, lenvatinib, cabozantinib and ramucirumab) have shown clinical benefit in the setting of phase III trials and one (i.e.,
nivolumab) has been granted accelerated approval based on a phase II trial, expanding, thus, the pipeline of effective drugs available in advanced HCC to providers.

- The improvement in the number of effective agents comes at a cost of increased complexity of clinical decision-making, and thus, in the design of future clinical trials.
- OS is still the most robust endpoint in advanced HCC but the increasing number of treatments after progression underscore the need for surrogate endpoints.
- PFS has a moderate correlation at trial level with OS (R=0.84). A conservative minimum surrogate threshold effect of HR $\leq 0.6$ is highly predictive of a significant improvement in OS, whereas HR ranging from 0.6 – 0.7 are uncertain surrogates.
- ORR by sensitive criteria in single arm phase II trials could be a useful tool to prioritize treatments for testing in phase III trials.

References


[89] Institute for Quality and Efficiency in Health Care [Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen] (IQWiG). Validity of surrogate endpoints in oncology: executive


Figure legends

Figure 1: Median overall survival of treatment modalities assessed in phase III trials for advanced hepatocellular carcinoma.
Treatments with more than one dot represent all the results obtained from different clinical trials testing the same compound. Trials are colored based on whether the final result was positive for superiority (green), negative (red) or positive for non-inferiority (orange) for the primary endpoint (OS). Placebo appears in blue. Relevant inclusion/exclusion criteria that may impact on median OS are: no portal vein invasion [13], no pulmonary metastases [37], sorafenib tolerant [22], MET high [23] and AFP>400ng/ml [25].

Figure 2: Treatment strategy for advanced hepatocellular carcinoma. Adapted from Llovet et al. Nat Rev Clin Oncol 2018[6].
Drugs in green have positive results from phase III trials with a superiority design (sorafenib in the first-line setting and regorafenib, cabozantinib and ramucirumab in the second-line setting). Drugs in orange have positive results from phase III trials with a non-inferiority design (lenvatinib in the first-line setting). Drugs in red have received accelerated approval from the FDA on the basis of promising efficacy results in phase II trials (nivolumab in the second-line setting). Key details of the patient populations are provided. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer (classification); ECOG PS: Eastern Cooperative Oncology Group performance status; EHS: extrahepatic spread; HCV: hepatitis C virus; HR: hazard ratio; mRECIST: modified Response Evaluation Criteria In Solid Tumors; ORR: objective response rate; OS: overall survival.

Figure 3: Correlation between surrogate endpoints (PFS[A] and TTP[B]) and hard endpoint (OS).
Trial-level correlation between endpoints using criteria from the Institute for Quality and Efficiency in Health Care (IQWIG). R and R2 refers to the weighted Pearson coefficient between the HR of OS and the HR of the surrogate endpoint. IQWIG categorizes the strength of the correlation based on the value of R as low (R<0.7), moderate (R>0.7 to R<0.85) and high (R>0.85)[89]. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate (TTP or PFS) and the hard endpoint (OS), respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.
Figure 4: Correlation between surrogate endpoints PFS and TTP.
Trial-level correlation between endpoints. R and R^2 refers to the weighted Pearson coefficient between the HR of PFS and the HR of TTP. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate TTP and PFS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.

Supplementary Figure 1: Correlation between objective response and OS.
Trial-level correlation between endpoints. R and R^2 refers to the weighted Pearson coefficient between the HR of OS and the odds ratio of objective response. Each dot represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the odds ratio for objective response and the HR for OS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the regression.

Tables

Table 1: Phase III trials in advanced hepatocellular carcinoma conducted in the last decade.
Table 2: Studies analyzing associations between radiological response and survival in hepatocellular carcinoma.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Arms</th>
<th>N</th>
<th>ORR</th>
<th>Median</th>
<th>PFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHARP (7)</td>
<td>Sorafenib</td>
<td>299</td>
<td>2.3</td>
<td>5.5</td>
<td>0.58 (0.48 - 0.74)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>303</td>
<td>0.7</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian-Pacific (6)</td>
<td>Sorafenib</td>
<td>160</td>
<td>3.3</td>
<td>2.8</td>
<td>0.37 (0.42 - 0.79)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>76</td>
<td>1.3</td>
<td>1.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JUN1170 (9)</td>
<td>Sorafenib</td>
<td>530</td>
<td>0.6</td>
<td>4.1</td>
<td>1.13 (0.96 - 1.31)</td>
<td>3.5</td>
</tr>
<tr>
<td>Placebo</td>
<td>544</td>
<td>0.1</td>
<td>3.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRISK-IP1 (10)</td>
<td>Sorafenib</td>
<td>677</td>
<td>12.0</td>
<td>4.2</td>
<td>1.91 (0.95 - 1.15)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>576</td>
<td>8.8</td>
<td>4.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIV1 (11)</td>
<td>Sorafenib</td>
<td>514</td>
<td>10.1</td>
<td>5.8</td>
<td>0.16 (0.64 - 0.99)</td>
<td>4.2</td>
</tr>
<tr>
<td>Placebo</td>
<td>521</td>
<td>6.1</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEARCH (12)</td>
<td>Sorafenib</td>
<td>362</td>
<td>3.9</td>
<td>4</td>
<td>1.14 (0.94 - 1.47)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>358</td>
<td>3.9</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REFLECT (13)</td>
<td>Sorafenib</td>
<td>478</td>
<td>24.1</td>
<td>8.6</td>
<td>0.63 (0.53 - 0.73)</td>
<td>7.4</td>
</tr>
<tr>
<td>Placebo</td>
<td>476</td>
<td>9.3</td>
<td>3.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRAH (14)</td>
<td>Sorafenib</td>
<td>237</td>
<td>15.2</td>
<td>NR</td>
<td>4.1</td>
<td>0.93 (0.65 - 1.25)</td>
</tr>
<tr>
<td>Placebo</td>
<td>222</td>
<td>10.4</td>
<td>3.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SILVESTRI1 (15)</td>
<td>Sorafenib</td>
<td>186</td>
<td>18.5</td>
<td>6.1</td>
<td>0.88 (0.77 - 1.11)</td>
<td>5.8</td>
</tr>
<tr>
<td>Placebo</td>
<td>178</td>
<td>1.7</td>
<td>5.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHO (16)</td>
<td>Sorafenib</td>
<td>188</td>
<td>9.2</td>
<td>NR</td>
<td>2.03</td>
<td>0.02 (0.49 - 0.76)</td>
</tr>
<tr>
<td>Placebo</td>
<td>167</td>
<td>2.7</td>
<td>1.77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALIBER0002 (17)</td>
<td>Sorafenib-Exon18</td>
<td>173</td>
<td>NR</td>
<td>NR</td>
<td>3.6</td>
<td>0.90 (0.72 - 1.19)</td>
</tr>
<tr>
<td>Placebo</td>
<td>173</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BILR109 (18)</td>
<td>Sorafenib-MHAC</td>
<td>103</td>
<td>36.3</td>
<td>5.3</td>
<td>0.65 (0.46 - 0.91)</td>
<td>4.8</td>
</tr>
<tr>
<td>Placebo</td>
<td>103</td>
<td>17.5</td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Second-line</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRISK-PF (19)</td>
<td>Sorafenib</td>
<td>203</td>
<td>9.6</td>
<td>4.2</td>
<td>0.56 (0.42 - 0.76)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>132</td>
<td>1.5</td>
<td>3.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIV1 (20)</td>
<td>Sorafenib</td>
<td>302</td>
<td>2.2</td>
<td>3</td>
<td>0.83 (0.73 - 1.15)</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td>302</td>
<td>2.2</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REACH (21)</td>
<td>Sorafenib</td>
<td>283</td>
<td>7.1</td>
<td>2.5</td>
<td>0.56 (0.46 - 0.71)</td>
<td>2.8</td>
</tr>
<tr>
<td>Placebo</td>
<td>292</td>
<td>0.7</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REKIR (22)</td>
<td>Sorafenib</td>
<td>379</td>
<td>10.6</td>
<td>6.2</td>
<td>0.94 (0.80 - 1.10)</td>
<td>5.5</td>
</tr>
<tr>
<td>Placebo</td>
<td>379</td>
<td>10.6</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METTAMICO (23)</td>
<td>Sorafenib</td>
<td>194</td>
<td>4.1</td>
<td>1.5</td>
<td>0.96 (0.74 - 1.28)</td>
<td>1.5</td>
</tr>
<tr>
<td>Placebo</td>
<td>226</td>
<td>0.0</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CELIESTA (24)</td>
<td>Sorafenib</td>
<td>114</td>
<td>0.0</td>
<td>3</td>
<td>0.86 (0.74 - 1.00)</td>
<td>2</td>
</tr>
<tr>
<td>Placebo</td>
<td>114</td>
<td>0.0</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REACH-3 (25)</td>
<td>Sorafenib</td>
<td>197</td>
<td>4.6</td>
<td>3.02</td>
<td>1.43 (0.31 - 5.98)</td>
<td>2.8</td>
</tr>
<tr>
<td>Placebo</td>
<td>197</td>
<td>11.1</td>
<td>1.61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADIPEC 20 (26)</td>
<td>Sorafenib</td>
<td>240</td>
<td>4.1</td>
<td>NR</td>
<td>2.64</td>
<td>0.08 (0.46 - 1.33)</td>
</tr>
<tr>
<td>Placebo</td>
<td>211</td>
<td>NR</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relive (27)</td>
<td>Sorafenib</td>
<td>233</td>
<td>0.8</td>
<td>NR</td>
<td>2.3</td>
<td>0.96 (0.74 - 1.29)</td>
</tr>
<tr>
<td>Placebo</td>
<td>234</td>
<td>0.7</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*RTT evaluation by mRECIST*  
NR = Not reported  
Green = Positive for superiority (p < 0.05)  
Orange = Positive for non-inferiority (Upper 95% CI < 1.05)  
Red = Negative for superiority or non-inferiority
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study</th>
<th>N</th>
<th>Radiological response</th>
<th>Median OS (HR/OR OS) [R vs Non-R]</th>
<th>Prediction of OS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Local ablation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RFA</td>
<td>Calabrese G et al (retrospective RFA)* (103)</td>
<td>151</td>
<td>CRR=78%</td>
<td>59.4m vs 25m (HR=0.3)</td>
<td>Yes (UV)</td>
</tr>
<tr>
<td>RFA/PEI</td>
<td>Sala et al (retrospective)* (106)</td>
<td>282</td>
<td>CRR=66%</td>
<td>43m vs 28m (OR=0.58)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAE/TACE</td>
<td>Gilmore R et al (retrospective) (106)</td>
<td>83</td>
<td>ORR=57%</td>
<td>20.7m vs 13.3m (HR=0.58)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>TACE</td>
<td>Kim BK et al (retrospective) (107)</td>
<td>292</td>
<td>ORR=71.9%</td>
<td>33.8m vs 17.1m (HR=0.48)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>TACE</td>
<td>Jung JS et al (retrospective) (108)</td>
<td>114</td>
<td>ORR=63.3%</td>
<td>41.1m vs 20.7m (HR=0.31)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>DEB TACE</td>
<td>Prajapat JI et al (retrospective) (109)</td>
<td>120</td>
<td>ORR=53.5%</td>
<td>28m vs 9.1m (HR=0.4)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Sorafenib Edeline J et al (retrospective) (98)</td>
<td>53</td>
<td>ORR=23%</td>
<td>18.2m vs 7.7m (NR)</td>
<td>Yes (UV)</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Sorafenib Ronot M (retrospective)** (99)</td>
<td>82</td>
<td>ORR=20%</td>
<td>25.5m vs 15.7m (HR=0.39)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Sorafenib Takada J (retrospective) (100)</td>
<td>191</td>
<td>ORR=15.1%</td>
<td>6.1m vs 10m (NR)</td>
<td>Yes (UV)</td>
</tr>
<tr>
<td><strong>Other systemic therapies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brivanib</td>
<td>Lencioni R et al (phase II trial) (101)</td>
<td>226</td>
<td>ORR=11.9%</td>
<td>14.3m vs 9.4m (HR=0.48)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>Nintedanib</td>
<td>Meyer T et al (2 phase II trials) (102)</td>
<td>180</td>
<td>ORR=15.0%</td>
<td>16.7m vs 10.9m (HR=0.62)</td>
<td>Yes (MV)</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>El-Khouery A et al (phase II trial)** (65)</td>
<td>145</td>
<td>ORR=14%</td>
<td>Non-reached vs 13.4m* (NR)</td>
<td>Yes (UV)</td>
</tr>
</tbody>
</table>

CRR = Complete response rate  
ORR = Objective response rate  
HR = Hazard ratio  
OR = Odds ratio  
m = months  
UV = Univariate  
MV = Multivariate  
NR = Non reported  
*EASL criteria  
**Non-R does not include stable disease  
***RECIST 1.1 criteria  
^0-25% reduction (17.7m); 0-25% increase (11.7m); >25% increase (8.9m).
Advanced stage (BCLC C: Portal invasion and/or extrahepatic spread)
Intermediate stage (BCLC B: Multinodular) progressing upon loco-regional therapies

1st line

- **Sorafenib**
  - OS HR=0.69 (vs Placebo)
  - Child-Pugh A - ECOG PS ≤2
  - *Higher benefit in HCV infection and lack of EHS

- **Lenvatinib**
  - OS HR=0.92 (vs Sorafenib)
  - Child-Pugh A - ECOG PS ≤1
  - No invasion main portal vein

PD

2nd line

- **Regorafenib**
  - OS HR=0.83 (vs Placebo)
  - Child-Pugh A - ECOG PS ≤1
  - Tolerant to sorafenib (≥65%)

- **Cabozantinib**
  - OS HR=0.76 (vs Placebo)
  - Child-Pugh A - ECOG PS ≤1

- **Ramucirumab**
  - OS HR=0.71 (vs Placebo)
  - Child-Pugh A - ECOG PS ≤1
  - AFP ≥ 400ng/ml

- **Nivolumab**
  - ORR=18% (mRECIST)
  - Child-Pugh A - ECOG PS ≤1
  - *PDL1 IHC not a predictive biomarker